The startup’s technology, Adoptive Cell Therapy (ACT), enhances patients’ immune cells to target cancer effectively.
US startup Fresh Wind Biotechnologies develops a platform that leverages vast biological datasets to inform and improve the development of personalized cancer treatments. The startup’s technology, Adoptive Cell Therapy (ACT), enhances patients’ immune cells to target cancer effectively. It also specializes in Tumor-Infiltrating Lymphocyte (TIL) therapy, which isolates, activates, and expands a patient’s T cells.